Researchers at Novartis are combining modern techniques with an old approach to drug discovery and getting surprising results.
Just as generic drugs have dramatically lowered the price of some common medicines and expanded access to them, so follow-on versions of complex biologic drugs to treat diseases like cancer and multiple sclerosis could benefit patients and reduce costs.
NIBR scientists do mini-sabbaticals with clinical researchers at other sites. Learn how they refresh their skills and boost scientific research.
Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.
This site is intended for a global audience.